Orforglipron Side Effects: What Studies Report

Where the orforglipron safety data come from

Orforglipron is an oral, non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, and the earliest human tolerability information was published from a phase 1a blinded, placebo-controlled single- and multiple-ascending-dose study in healthy participants (PMID 37344954). A companion phase 1b multiple-ascending-dose study extended those observations to people with type 2 diabetes (PMID 37264711). Because orforglipron is a small molecule rather than a peptide, reviews of its development programme have discussed its oral administration without the food and water restrictions associated with peptide-based oral GLP-1 products (PMID 41275408).

The larger adverse-event datasets come from randomised trials in obesity and type 2 diabetes. A phase 2 trial in adults with obesity randomised participants to orforglipron 12, 24, 36 or 45 mg once daily or placebo over 36 weeks (PMID 37351564). A phase 2 dose-response trial in type 2 diabetes evaluated orforglipron doses of 12, 24, 36 and 45 mg once daily alongside placebo and dulaglutide 1.5 mg (PMID 37369232). In phase 3, a 72-week obesity trial studied orforglipron 6, 12 and 36 mg once daily against placebo (PMID 40960239), and a trial in early type 2 diabetes studied 3, 12 and 36 mg once daily (PMID 40544435). A further phase 3 trial, ACHIEVE-3, compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes in a multinational, open-label, non-inferiority design (PMID 41765029).

Gastrointestinal Adverse Events: What Studies Report

Across the published trials, the dominant adverse-event category was gastrointestinal. In the phase 2 obesity trial, researchers reported that the most frequently observed adverse events were gastrointestinal and that they were generally mild to moderate in severity (PMID 37351564). The phase 3 obesity trial likewise reported gastrointestinal events — including nausea, vomiting, diarrhoea and constipation — as the most common adverse events with orforglipron over 72 weeks (PMID 40960239). In early type 2 diabetes, the study reported a similar gastrointestinal profile across the 3, 12 and 36 mg groups (PMID 40544435), and the phase 2 dose-response diabetes trial reported gastrointestinal events as the most common adverse events across the 12–45 mg range (PMID 37369232).

Earlier-phase work pointed in the same direction. Investigators in the phase 1a study in healthy participants reported that adverse events were predominantly gastrointestinal and dose-related (PMID 37344954), and the phase 1b study in people with type 2 diabetes reported a comparable pattern during multiple ascending dosing (PMID 37264711).

Severity and dose relationship

Published reports consistently characterised the gastrointestinal events as mild to moderate rather than severe, with frequency generally rising at higher doses; the phase 2 obesity trial described this dose-related pattern across 12 to 45 mg once daily (PMID 37351564), and the phase 3 obesity trial reported gastrointestinal events across the 6, 12 and 36 mg groups with placebo as comparator (PMID 40960239). A 2025 systematic review and meta-analysis of orforglipron in obese adults with or without diabetes reported that gastrointestinal adverse events were more frequent with orforglipron than with placebo when trial data were pooled (PMID 41296780).

Dose Escalation and Timing: What Studies Report

Timing was a recurring theme. Researchers in the phase 2 obesity trial reported that gastrointestinal adverse events occurred most often during the dose-escalation period rather than during maintenance dosing (PMID 37351564). The phase 3 trials used stepwise escalation schedules toward target doses of up to 36 mg once daily, and the published reports described tolerability in that context (PMID 40960239) (PMID 40544435). Reviews of incretin-based obesity pharmacotherapy have discussed gradual dose escalation as the standard trial approach to managing gastrointestinal tolerability across this drug class (PMID 39952695).

Discontinuation and Tolerability: What Studies Report

Discontinuation because of adverse events is the metric trials use to summarise net tolerability. The phase 2 obesity trial reported that discontinuation due to adverse events was more frequent in the orforglipron groups than in the placebo group (PMID 37351564). The 72-week phase 3 obesity trial similarly reported more adverse-event-related discontinuations with orforglipron than with placebo (PMID 40960239), and the early type 2 diabetes trial reported discontinuation rates alongside its efficacy outcomes for the 3, 12 and 36 mg doses (PMID 40544435). The pooled analysis reported that, despite the higher frequency of gastrointestinal events, most were not severe (PMID 41296780).

Trials that contributed adverse-event data

Appetite and weight-related observations

Decreased appetite is a pharmacological consequence of GLP-1 receptor agonism rather than an incidental finding, and trials recorded it alongside gastrointestinal events. The phase 2 obesity trial reported dose-related weight reduction across 12 to 45 mg once daily at week 36 (PMID 37351564), and the 72-week phase 3 obesity trial reported greater weight reduction with orforglipron than with placebo (PMID 40960239). In type 2 diabetes, the phase 3 trial reported reductions in glycated haemoglobin with orforglipron compared with placebo in early disease (PMID 40544435). Reviews of emerging obesity pharmacotherapy have discussed how the same mechanism that produces weight and glycaemic effects also produces the gastrointestinal tolerability profile seen across incretin agents (PMID 39952695).

Comparisons with Other GLP-1 Agents: What Studies Report

Head-to-head and indirect comparisons have been published. The ACHIEVE-3 phase 3 trial compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes and reported both efficacy and safety outcomes in an open-label, non-inferiority framework (PMID 41765029). Separately, a population-adjusted indirect treatment comparison evaluated oral semaglutide 25 mg against orforglipron 36 mg in obesity, using statistical adjustment rather than randomised head-to-head data (PMID 42225305). Indirect comparisons of this kind carry assumptions that the authors themselves describe, so the researchers' caveats matter as much as the point estimates (PMID 42225305). Broader commentary on multi-receptor agonists and next-generation metabolic modulators has placed orforglipron's tolerability within an evolving landscape in which cross-trial differences in escalation schedules complicate direct safety comparisons (PMID 41948476).

What the literature does not yet establish

Several limits are stated in the source material itself. The phase 1 studies were short and enrolled small numbers of participants, so they were designed to characterise dose-ranging tolerability rather than rare events (PMID 37344954). Phase 2 trials ran for a matter of months, which the obesity study reflected in its 36-week design (PMID 37351564), and even the longest published obesity trial reported outcomes at 72 weeks (PMID 40960239). ACHIEVE-3 was open label, a design feature the investigators noted in the trial description (PMID 41765029). The published meta-analysis pooled a limited number of trials, and its authors framed their conclusions accordingly (PMID 41296780). Review articles have highlighted that longer-term outcome data, real-world persistence and comparative effectiveness against established injectable and oral incretin therapies remain areas of active investigation (PMID 41275408) (PMID 41948476).

It also matters who was studied. The randomised trials enrolled defined populations — adults with obesity, or adults with type 2 diabetes, including a trial specifically in early type 2 diabetes (PMID 40544435) — with eligibility criteria and monitoring that differ from unstudied settings. Adverse-event frequencies reported under trial conditions describe those cohorts and those escalation schedules, not other circumstances.

How to read published adverse-event tables

• Frequency is context-dependent. Rates reported for a given dose reflect the escalation schedule and duration used in that specific trial, such as the 6, 12 and 36 mg arms of the phase 3 obesity trial (PMID 40960239).
• Severity grading is separate from frequency. Researchers described most gastrointestinal events as mild to moderate even where they were common (PMID 37351564).
• Discontinuation captures net tolerability. Both the phase 2 and phase 3 obesity trials reported higher adverse-event discontinuation with orforglipron than placebo (PMID 37351564) (PMID 40960239).
• Pooled estimates smooth trial differences. The systematic review and meta-analysis combined obesity trials with and without diabetes, reporting an overall increase in gastrointestinal events versus placebo (PMID 41296780).

Regulatory and status note

Regulatory status changes over time and differs by jurisdiction. Published reviews have described orforglipron as an investigational oral small-molecule GLP-1 receptor agonist advancing through late-phase clinical development for type 2 diabetes and obesity (PMID 41275408). This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional for any question about a medication, a health condition or clinical trial participation.

References

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (The New England Journal of Medicine, 2025)
• Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (The New England Journal of Medicine, 2023)
• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (The New England Journal of Medicine, 2025)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison (Diabetes, Obesity & Metabolism, 2026)
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study (Lancet, 2023)
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial (Lancet, 2026)
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants (Diabetes, Obesity & Metabolism, 2023)
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes (Diabetes, Obesity & Metabolism, 2023)
• Orforglipron in type 2 diabetes mellitus and obesity: an overview (Expert Review of Clinical Pharmacology, 2025)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis (Endocrinology, Diabetes & Metabolism, 2025)